Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens.Observational.We first calculated RATE-sparing options available to an ave...

Full description

Bibliographic Details
Main Authors: Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4072535?pdf=render

Internet

http://europepmc.org/articles/PMC4072535?pdf=render

Similar Items